'For quarter ending June 2024, consolidated Net sales (including other operating income) of Emami has increased 9.74% to Rs 906.07 crore compared to quarter ended June 2023. Operating profit margin has jumped from 23.01% to 23.90%, leading to 13.95% rise in operating profit to Rs 216.51 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 20.43% to 16.14%. Purchase of finished goods cost rose from 12.28% to 13.14%. Employee cost increased from 12.64% to 12.81%. Other expenses rose from 30.98% to 32.94%. Selling and administration expenses rose from 18.92% to 21.19%.
Other income rose 26.33% to Rs 10.46 crore. PBIDT rose 14.46% to Rs 226.97 crore. Provision for interest fell 3.74% to Rs 2.06 crore.
PBDT rose 14.66% to Rs 224.91 crore. Provision for depreciation fell 3.41% to Rs 44.43 crore.
Pro...
Pleaselogin & subscribe to view the full report.
More Reports
-
(05-Nov-2024)
Gland Pharma
-
-
NII growth improves to 4% in Q2FY25
-
Revenue up 6.9% YoY to Rs 1064.0 cr, PAT up 4.5% YoY to Rs 307.9cr in Q2FY2025
|
|